CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 183 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02948088
NCT02948088N/ACompleted

A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Daiichi Sankyo·observational·Posted Oct 28, 2016·Updated Oct 31, 2023

In Brief

An observational study for Giant Cell Tumors. Completed, enrolled 183 participants across 15 sites in 8 countries.

Detailed Summary

TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of d-TGCT. This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States
CollaboratorsOptimapharm

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 28, 2016
Enrollment StartNov 18, 2016
Primary CompletionMar 11, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.7 years ago